Thomas Oxley – Revolutionizing Brain-Computer Interfaces Through Minimally Invasive Methods
Thomas Oxley, MD, PhD, is a neurologist and founder of Synchron, as well as an Associate Professor at University of Melbourne.
https://profiles.mountsinai.org/thomas-j-oxley
********
BrainMind Special Forum in Neuromodulation/BCI/AI
In this talk, Dr. Oxley discusses the revolutionary approach his company, Synchron, is taking to advance brain-computer interfaces (BCIs) using minimally invasive methods. Drawing parallels to the evolution of interventional cardiology, he explains how the same principles of delivering technology through blood vessels can be applied to neurotechnology. By avoiding open brain surgery, Synchron aims to scale the delivery of BCIs, making them more accessible. Dr. Oxley highlights the progress of their first product, the Stentrode, which has shown promising results in clinical trials and is poised to transform the treatment of neurological conditions.
See other talks from this forum: https://www.youtube.com/playlist?list=PL85qrIdmUGCqh988X0Qy3-OcOGXuRmJHI
********
BrainMind is a platform and private community of top brain scientists, entrepreneurs, investors, philanthropists, and academic institutions collaborating to accelerate impactful innovation in brain science.
https://www.brainmind.org/
Apply to become a member of the BrainMind ecosystem:
https://www.brainmind.org/application
Thomas Oxley, MD, PhD, is a neurologist and founder of Synchron, as well as an Associate Professor at University of Melbourne.
https://profiles.mountsinai.org/thomas-j-oxley
********
BrainMind Special Forum in Neuromodulation/BCI/AI
In this talk, Dr. Oxley discusses the revolutionary approach his company, Synchron, is taking to advance brain-computer interfaces (BCIs) using minimally invasive methods. Drawing parallels to the evolution of interventional cardiology, he explains how the same principles of delivering technology through blood vessels can be applied to neurotechnology. By avoiding open brain surgery, Synchron aims to scale the delivery of BCIs, making them more accessible. Dr. Oxley highlights the progress of their first product, the Stentrode, which has shown promising results in clinical trials and is poised to transform the treatment of neurological conditions.
See other talks from this forum: https://www.youtube.com/playlist?list=PL85qrIdmUGCqh988X0Qy3-OcOGXuRmJHI
********
BrainMind is a platform and private community of top brain scientists, entrepreneurs, investors, philanthropists, and academic institutions collaborating to accelerate impactful innovation in brain science.
https://www.brainmind.org/
Apply to become a member of the BrainMind ecosystem:
https://www.brainmind.org/application
